On Jan. 13, 2021, SIGA Technologies announced that the Public Health Agency of Canada had awarded a contract to Meridian Medical Technologies, a Pfizer Company, for the purchase up to approximately $33 million of oral TPOXX (tecovirimat) within five years.

The Contract specified firm commitments for the purchase of approximately $3.4 million of oral TPOXX by Mar. 31, 2021 and a cumulative purchase of approximately $17.2 million of oral TPOXX by Mar. 31, 2023.